viewInvion Ltd

Invion Limited in pre-open to raise funds


Australian drug development company Invion Limited (ASX: IVX) has been granted a trading halt by the ASX this morning, with its shares placed in pre-open, pending a capital raising announcement.

Invion has two drug assets in three FDA-regulated, phase II clinical programs, with the company focusing on the development of treatments for inflammatory diseases, including asthma, COPD and lupus.

Estimates have the prescription respiratory world market $64.6 billion, and the asthma and COPD prescription drugs at $34 billion - which Invion is targeting.

The halt will last until the earlier of an announcement being made to the market, or the opening of trade on Tuesday 11th June 2013.


Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

Quick facts: Invion Ltd

Price: 0.007 AUD

Market: ASX
Market Cap: $38.5 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Australian gold producers making 'excellent margins and may start to hedge'

Alto Capital's Tony Locantro says he can see a great deal of volatility ahead for the gold price. He adds that once we're out the other side of this current health crisis the participation rate in gold is going to increase. ''Australia gold producers are making excellent margins and I...

1 day, 1 hour ago

2 min read